Therapeutic Antibodies – Webinars and Online Events

The global market for antibody therapeutics is rising rapidly and newer, engineered modalities such as bi-specific antibodies and antibody fragments are entering clinical studies in record numbers.

In this webinar, our expert speaker Dr. Phillip Kim from the University of Toronto will be discussing the ML methods he currently implements in his lab that enables de novo antibody design. He will also cover ML-based sequence design and scoring methods, as well as diffusion models.

Charge heterogeneity is often a critical quality attribute, which must be monitored throughout the development of a therapeutic protein and during quality control release.

This exclusive Technology Networks webinar focuses on the most recent and innovative strategies for therapeutic antibody development and production. Your speaker, Professor Brockwell, will describe the development and use of a new assay to investigate important proteins in disease screening and the biopharmaceutical industry.

This webinar discusses an analytical approach for N-linked glycan analysis using the SLIM-based high-resolution ion mobility platform MOBIE. Results will be shown for each aspect of the overall strategy and how this platform can be an integral part for the characterization of protein therapeutics.

To combat the COVID-19 pandemic, comprehensive characterization of humoral and cellular immune responses to SARS-CoV-2 is essential.

New methods, techniques and efficient data analysis software in liquid chromatography-tandem mass spectrometry (LC-MS/MS) hold the key for accelerating the development of NGBs and increasing their availability.

Biopharmaceutical companies are transitioning from the development of standard monoclonal antibody therapies to more intricate antibody structures and new genetic medicines. Not only are these molecules more complex, but scientists are also under tremendous pressure to understand molecular liabilities sooner and close the developability gap in a much shorter time frame.

Vanderbilt University Medical Center researchers Robert Carnahan and Pavlo Gilchuk are attempting to compress the timeline for therapeutic antibody development, by integrating a series of advances in single-cell messenger RNA sequence analysis, bioinformatics, synthetic biology and high-throughput functional analysis.